keyword
MENU ▼
Read by QxMD icon Read
search

Panitumumab

keyword
https://www.readbyqxmd.com/read/28089687/stabilizing-effects-for-antibody-formulations-and-safety-profiles-of-cyclodextrin-polypseudorotaxane-hydrogels
#1
Taishi Higashi, Naoko Ohshita, Tatsunori Hirotsu, Yoshihito Yamashita, Keiichi Motoyama, Sawako Koyama, Ruriko Iibuchi, Takayuki Uchida, Shiuhei Mieda, Kenji Handa, Tomoaki Kimoto, Hidetoshi Arima
Antibodies often have poor physicochemical stability during storage and/or transport, which is a serious drawback for the development of antibody-based drugs. In this study, we prepared polypseudorotaxane (PPRX) hydrogels consisting of cyclodextrins (CyDs) and polyethylene glycol (PEG), and evaluated them as stabilizers for commercially available antibody-based drugs. α-CyD and γ-CyD formed PPRX hydrogels with PEG (MW 20,000 Da) in the presence of antibody-based drugs such as omalizumab, palivizumab, panitumumab, and ranibizumab...
January 12, 2017: Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/28056412/toxicity-of-concurrent-stereotactic-radiotherapy-and-targeted-therapy-or-immunotherapy-a-systematic-review
#2
REVIEW
Stephanie G C Kroeze, Corinna Fritz, Morten Hoyer, Simon S Lo, Umberto Ricardi, Arjun Sahgal, Rolf Stahel, Roger Stupp, Matthias Guckenberger
BACKGROUND AND PURPOSE: Both stereotactic radiotherapy (SRT) and immune- or targeted therapy play an increasingly important role in personalized treatment of metastatic disease. Concurrent application of both therapies is rapidly expanding in daily clinical practice. In this systematic review we summarize severe toxicity observed after concurrent treatment. MATERIAL AND METHODS: PubMed and EMBASE databases were searched for English literature published up to April 2016 using keywords "radiosurgery", "local ablative therapy", "gamma knife" and "stereotactic", combined with "bevacizumab", "cetuximab", "crizotinib", "erlotinib", "gefitinib", "ipilimumab", "lapatinib", "sorafenib", "sunitinib", "trastuzumab", "vemurafenib", "PLX4032", "panitumumab", "nivolumab", "pembrolizumab", "alectinib", "ceritinib", "dabrafenib", "trametinib", "BRAF", "TKI", "MEK", "PD1", "EGFR", "CTLA-4" or "ALK"...
December 19, 2016: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/28040660/quality-of-life-and-swallowing-with-standard-chemoradiotherapy-versus-accelerated-radiotherapy-and-panitumumab-in-locoregionally-advanced-carcinoma-of-the-head-and-neck-a-phase-iii-randomised-trial-from-the-canadian-cancer-trials-group-hn-6
#3
Jolie Ringash, John N Waldron, Lillian L Siu, Rosemary Martino, Eric Winquist, Jim R Wright, Abdenour Nabid, John H Hay, Alex Hammond, Khalil Sultanem, Sebastien Hotte, Carson Leong, Ali Abdel Halim El-Gayed, Farah Naz, Kevin Ramchandar, Timothy E Owen, Alexander Montenegro, Brian O'Sullivan, Bingshu E Chen, Wendy R Parulekar
AIM: To compare quality of life (QOL) between standard (SFX) chemoradiotherapy (arm A) and altered fractionation radiotherapy (AFX) with panitumumab (PMab; arm B). METHODS: Patients with T any N + M0 or T3-4N0M0 squamous cell head-neck carcinoma were randomised to SFX (70 Gy/35/7 wks) plus cisplatin (100 mg/m(2) IV × 3) versus AFX (70 Gy/35/6 wks) plus PMab (9 mg/kg IV × 3). QOL was collected at baseline, end of radiation therapy (RT) and 2, 4, 6, 12, 24 and 36 months post-RT using the Functional Assessment of Cancer Therapy Head and Neck (FACT-H&N), MD Anderson Dysphagia Index (MDADI) and SWAL-QOL...
December 29, 2016: European Journal of Cancer
https://www.readbyqxmd.com/read/28038457/preclinical-efficacy-of-sym004-novel-anti-egfr-antibody-mixture-in-esophageal-squamous-cell-carcinoma-cell-lines
#4
Shota Fukuoka, Takashi Kojima, Yoshikatsu Koga, Mayumi Yamauchi, Masayuki Komatsu, Rie Komatsuzaki, Hiroki Sasaki, Masahiro Yasunaga, Yasuhiro Matsumura, Toshihiko Doi, Atsushi Ohtsu
Epidermal growth factor receptor (EGFR) is a well-validated oncological target molecule for monoclonal antibody therapies and Sym004 is a novel anti-EGFR antibody mixture comprising two recombinant chimeric IgG1 antibodies against non-overlapping epitopes of EGFR. Because EGFR is highly expressed in the majority of esophageal squamous cell carcinomas (ESCCs), we investigated the efficacy of Sym004 in human ESCC cell lines. Forty eight ESCC cell lines were treated with three kinds of anti-EGFR antibodies (Sym004, cetuximab, and panitumumab)...
December 26, 2016: Oncotarget
https://www.readbyqxmd.com/read/28032593/the-impact-of-co-expression-of-wild-type-egfr-and-its-ligands-determined-by-immunohistochemistry-for-response-to-treatment-with-cetuximab-in-patients-with-metastatic-colorectal-cancer
#5
Said Khelwatty, Sharadah Essapen, Izhar Bagwan, Margaret Green, Alan Seddon, Helmout Modjtahedi
Anti-EGFR mAbs cetuximab and panitumumab are routinely used for the treatment of patients with KRAS-wild type metastatic colorectal cancer (mCRC). However, in some patients their efficacy remains modest and with no clear association between the EGFR protein expression determined by PharmDx™ kit, and response to anti-EGFR therapies. Therefore, we investigated the relative expression and predictive value of wild-type EGFR (wtEGFR), mutated EGFRvIII and EGFR ligand proteins in mCRC patients treated with cetuximab...
December 9, 2016: Oncotarget
https://www.readbyqxmd.com/read/28025473/-target-therapy-in-unresectable-or-metastatic-colorectal-cancer
#6
REVIEW
Jae Hyun Kim, Seun Ja Park
Colorectal cancer (CRC) is the third most commonly diagnosed cancer in Korea. Despite recent developments in the treatment of CRC, the median overall survival time in patients with metastatic CRC is less than 30 months. The biologic agents that target the epidermal growth factor receptor (EGFR) or vascular endothelial growth factor (VEGF) have proven clinical benefits in the treatment of patient with metastatic CRC. Anti-EGFR agents, including cetuximab and panitumumab, as well as anti-VEGF agents, including bevacizumab, aflibercept, ramucirumab, and regorafenib have been shown to extend survival in combination with cytotoxic chemotherapy...
December 25, 2016: Korean Journal of Gastroenterology, Taehan Sohwagi Hakhoe Chi
https://www.readbyqxmd.com/read/28008206/aggressive-resection-of-frequent-peritoneal-recurrences-in-colorectal-cancer-contributes-to-long-term-survival
#7
Koji Komori, Takashi Kinoshita, Oshiro Taihei, Seiji Ito, Tetsuya Abe, Yoshiki Senda, Kazunari Misawa, Yuich Ito, Norihisa Uemura, Seiji Natsume, Jiro Kawakami, Akira Ouchi, Masayuki Tsutsuyama, Takahiro Hosoi, Itaru Shigeyoshi, Tomoyuki Akazawa, Daisuke Hayashi, Hideharu Tanaka, Yasuhiro Shimizu
We report a long-term survivor of colorectal cancer who underwent aggressive, frequent resection for peritoneal recurrences. A 58-year-old woman was diagnosed with descending colon cancer. Resection of the descending colon along with lymph node dissection was performed in September 2006. The pathological findings revealed Stage IIA colorectal cancer. The following peritoneal recurrences were removed: two in July 2007, two in the omental fat and two in the pouch of Douglas in June 2008 resected by low anterior resection of the rectum, one in the uterus and right ovarian recurrence resected via bilateral adnexectomy and Hartmann's procedure in May 2011, and one in the ascending colon by partial resection of the colon wall in December 2011...
December 2016: Nagoya Journal of Medical Science
https://www.readbyqxmd.com/read/27993089/immunotherapy-of-colorectal-cancer-new-perspectives-after-a-long-path
#8
Pierpaolo Correale, Cirino Botta, Domenico Ciliberto, Pierpaolo Pastina, Rossana Ingargiola, Silvia Zappavigna, Pierfrancesco Tassone, Luigi Pirtoli, Michele Caraglia, Pierosandro Tagliaferri
Although significant therapeutic improvement has been achieved in the last 10 years, the survival of metastatic colorectal cancer patients remains in a range of 28 to 30 months. Presently, systemic treatment includes combination chemotherapy with oxaliplatin and/or irinotecan together with a backbone of 5-fluorouracil/levofolinate, alone or in combination with monoclonal antibodies to VEGFA (bevacizumab) or EGF receptor (cetuximab and panitumumab). The recent rise of immune checkpoint inhibitors in the therapeutic scenario has renewed scientific interest in the investigation of immunotherapy in metastatic colorectal cancer patients...
November 2016: Immunotherapy
https://www.readbyqxmd.com/read/27977573/the-efficacy-and-safety-of-panitumumab-plus-irrinotecan-based-chemotherapy-in-the-treatment-of-metastatic-colorectal-cancer-a-meta-analysis
#9
Qiang Chen, Minjing Cheng, Zhuo Wang, Shipeng Zhao
BACKGROUND: Panitumumab, a fully human monoclonal antibody targeting epidermal growth factor receptor, is used in combination with chemotherapy for patients with metastatic colorectal cancer (mCRC). However, the effects of panitumumab in combination with irrinotecan-based chemotherapy remain uncertain. Therefore, we conducted this meta-analysis to assess the efficacy and safety of combination treatment of panitumumab plus chemotherapy in the treatment of mCRC. METHODS: By searching electronic databases (PubMed, Embase, and Web of Science), all clinical trials which assessed the effects of panitumumab plus irrinotecan-based chemotherapy in mCRC would be included...
December 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27972546/cost-minimization-analysis-of-bevacizumab-compared-to-cetuximab-and-panitumumab-in-first-line-treatment-of-kras-wild-type-metastatic-colorectal-cancer-in-france
#10
A Gherardi, C Masia, N Plommet
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27972544/cost-minimization-analysis-of-bevacizumab-versus-cetuximab-and-panitumumab-in-the-management-of-colorectal-cancer-from-patient-perspective-in-egypt
#11
M F Ragab, R A Assal, M M Abdelrahman, G Elsisi
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27972543/cost-minimization-analysis-of-panitumumab-compared-with-cetuximab-in-the-first-line-treatment-of-wild-type-ras-metastatic-colorectal-cancer-patients-in-brazil
#12
R F Dos Santos, B S Riveros, M E Nita, G O Pedro
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27972542/cost-minimization-analysis-of-panitumumab-vs-cetuximab-as-monotherapy-for-chemo-refractory-patients-with-wt-kras-mcrc-in-mexico
#13
M E Alva, M Naranjo, J Zamora
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27972389/efficacy-and-safety-of-panitumumab-in-patients-of-metastatic-colorectal-cancer-by-tumor-kras-status-a-systematic-review
#14
R Singh, N Sharma, P Rana, S Baig, S Singh, M K Rai
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27965461/kras-mutant-colorectal-cancer-gene-signatures-identified-angiotensin-ii-receptor-blockers-as-potential-therapies
#15
Qing Wen, Philip D Dunne, Paul G O'Reilly, Gerald Li, Anthony J Bjourson, Darragh G McArt, Peter W Hamilton, Shu-Dong Zhang
Colorectal cancer (CRC) is a life-threatening disease with high prevalence and mortality worldwide. The KRAS oncogene is mutated in approximately 40% of CRCs. While antibody based EGFR inhibitors (cetuximab and panitumumab) represent a major treatment strategy for advanced KRAS wild type (KRAS-WT) CRCs, there still remains no effective therapeutic course for advanced KRAS mutant (KRAS-MT) CRC patients.In this study, we employed a novel and comprehensive approach of gene expression connectivity mapping (GECM) to identify candidate compounds to target KRAS-MT tumors...
December 10, 2016: Oncotarget
https://www.readbyqxmd.com/read/27943689/role-of-biologics-in-first-line-treatment-of-colorectal-cancer
#16
Amit Mahipal, Axel Grothey
In the past decade, significant advances have been made in the treatment of advanced colorectal cancer. Multiple cytotoxic agents and targeted therapies have been approved for management of metastatic colorectal cancer, leading to improvement of median overall survival in clinical trials to more than 30 months. Of note, before the introduction of biologics into treatment algorithms for metastatic colorectal cancer, median survival in phase III trials never exceeded 24 months. In 2016, the most common treatment approach in first line is a combination of chemotherapy with a biologic agent...
December 2016: Journal of Oncology Practice
https://www.readbyqxmd.com/read/27930762/effect-of-standard-radiotherapy-with-cisplatin-vs-accelerated-radiotherapy-with-panitumumab-in-locoregionally-advanced-squamous-cell-head-and-neck-carcinoma-a-randomized-clinical-trial
#17
Lillian L Siu, John N Waldron, Bingshu E Chen, Eric Winquist, Jim R Wright, Abdenour Nabid, John H Hay, Jolie Ringash, Geoffrey Liu, Ana Johnson, George Shenouda, Martin Chasen, Andrew Pearce, James B Butler, Stephen Breen, Eric Xueyu Chen, T J FitzGerald, T J Childs, Alexander Montenegro, Brian O'Sullivan, Wendy R Parulekar
Importance: The Canadian Cancer Trials Group study HN.6 is the largest randomized clinical trial to date comparing the concurrent administration of anti-epidermal growth factor receptor (EGFR) monoclonal antibodies with radiotherapy (RT) to standard chemoradiotherapy in locoregionally advanced squamous cell carcinoma of the head and neck (LA-SCCHN). Objective: To compare progression-free survival (PFS) in patients with LA-SCCHN treated with standard-fractionation RT plus high-dose cisplatin vs accelerated-fractionation RT plus the anti-EGFR antibody panitumumab...
December 8, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27929064/acquired-ras-or-egfr-mutations-and-duration-of-response-to-egfr-blockade-in-colorectal-cancer
#18
Beth O Van Emburgh, Sabrina Arena, Giulia Siravegna, Luca Lazzari, Giovanni Crisafulli, Giorgio Corti, Benedetta Mussolin, Federica Baldi, Michela Buscarino, Alice Bartolini, Emanuele Valtorta, Joana Vidal, Beatriz Bellosillo, Giovanni Germano, Filippo Pietrantonio, Agostino Ponzetti, Joan Albanell, Salvatore Siena, Andrea Sartore-Bianchi, Federica Di Nicolantonio, Clara Montagut, Alberto Bardelli
Blockade of the epidermal growth factor receptor (EGFR) with the monoclonal antibodies cetuximab or panitumumab is effective in a subset of colorectal cancers (CRCs), but the emergence of resistance limits the efficacy of these therapeutic agents. At relapse, the majority of patients develop RAS mutations, while a subset acquires EGFR extracellular domain (ECD) mutations. Here we find that patients who experience greater and longer responses to EGFR blockade preferentially develop EGFR ECD mutations, while RAS mutations emerge more frequently in patients with smaller tumour shrinkage and shorter progression-free survival...
December 8, 2016: Nature Communications
https://www.readbyqxmd.com/read/27878479/total-transthoracic-approach-facilitates-laparoscopic-hepatic-resection-in-patients-with-significant-prior-abdominal-surgery
#19
Suguru Yamashita, Evelyne Loyer, Hyunseon C Kang, Thomas A Aloia, Yun Shin Chun, Reza J Mehran, Cathy Eng, Jeffrey E Lee, Jean-Nicolas Vauthey, Claudius Conrad
BACKGROUND: While the oncologic safety of minimally invasive hepatectomy for colorectal liver metastases (CLM) has been demonstrated, lesions in the postero-superior segments may be challenging.1 (-) 3 For these lesions, a transthoracic approach may be particularly helpful, especially in patients with a hostile/reoperative abdomen or morbid obesity.4 (,) 5 PATIENT: A 43-year-old man with a body mass index of 36.0 who had undergone rectosigmoid resection for primary cancer 5 years ago recurred with a solitary liver metastasis in SVIII...
November 22, 2016: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/27872609/panitumumab-associated-encephalopathy-after-accidental-intra-arterial-application-through-dislocated-central-venous-access-device
#20
Slaven Pikija, Georg Pilz, Gerald Gschwandtner, Cornelia Rösler, Konstantin Schlick, Richard Greil, Johann Sellner
Acute central nervous system (CNS) toxicity and immune-related side effects are increasingly recognized with the use of monoclonal antibodies for cancer therapy. Here, we report a patient who developed of acute-onset encephalopathy and coma, which began shortly after administration of panitumumab for the treatment of metastatic colorectal cancer. Echocardiography revealed that the drug had been infused into the left cardiac ventricle via a dislocated central venous line. Diffusion-weighted magnetic resonance imaging disclosed multiple cortical hyperintensities, which were preferentially located in the frontal lobes...
2016: Frontiers in Neurology
keyword
keyword
16315
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"